Navigation Links
Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research
Date:9/8/2009

vel cancer therapy, culminating in the production of an anti-HER2 monoclonal antibody that since 1998 has been used successfully to treat patients with metastatic breast cancer. This was the first targeted drug developed on the basis of a newly discovered gene associated with a cancer causing function in humans.

In the early 1990s, Ullrich identified the signaling system involved in regulating tumor angiogenesis, the growth of blood vessels in tumors. He discovered that inhibiting a key player in the signaling system (called vascular endothelial growth factor receptor or VEGFR) suppresses the generation of blood vessels in tumors and slows down cancer cell growth. Years later, a small molecule inhibitor of the VEGFR2 kinase function was developed, from which a derivative was approved in 2006 for the treatment of kidney carcinoma and gastro-intestinal stromal tumors.

"It is an honor to be recognized with an award of this stature," said Ullrich. "Dr. Paul was a highly respected scientist whose work continues to extend and improve the lives of people all over the world. I am truly humbled to be selected as the recipient of an award whose namesake carries on his tremendous legacy."

"Dr. Ullrich is one of the few basic scientists whose work directly affects the lives of countless patients suffering from major chronic diseases," said Paul Stoffels, M.D., global head, Research & Development, Pharmaceuticals, Johnson & Johnson. "We are proud to present The Dr. Paul Janssen Award to such a passionate pioneer in biomedical research."

Ullrich has previously received prestigious honors and awards, including the Robert Koch Prize, the Bruce F. Cain Memorial Award of the American Association of Cancer Research and the King Faisal Prize of Medicine.

About The Dr. Paul Janssen Award

Established by Johnson & Johnson, The Dr. Paul Ja
'/>"/>

SOURCE Johnson & Johnson
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
2. Johnson & Johnson Completes Acquisition of Cougar Biotechnology
3. Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
4. Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
5. Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
6. Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
7. Simbionix and Johnson & Johnson LLC Announce a Distribution Agreement for Russia and the CIS Countries
8. Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
9. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
10. Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
11. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
(Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
(Date:10/20/2014)... , October 20, 2014 ... gastrointestinal (GI) disorders and the delivery of care has ... diseases and worrying inequalities in the provision of healthcare ... which was commissioned by United European Gastroenterology (UEG), have ... political and public awareness of the burden of GI ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Partners LLC, announced today that Ellen Teplitzky, an ... support for the pharmaceutical industry, has joined the ... of its legal services practice. NDA Partners ... expert witness and testimony, to top law firms ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... Executive Team, FREMONT, Calif., Sept. 8 ... a novel transdermal,delivery technology, today announced that Gail ... The company also announced several recent,appointments to the ... and president; John M. Vuko, executive vice president ...
... Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it ... trial using intravenous,administration of REOLYSIN(R) in combination with ... neck cancers. The Principal,Investigator is Dr. Monica Mita ... The University of Texas Health Science Center at ...
... Md., Sept. 8 Neuralstem Inc., CEO,Richard Garr, will ... Lateral Sclerosis, or Lou Gehrig,s disease) at the 2008 ... at 2:00 CDT. In a,presentation prior to the panel, ... trial and give an update of the Company,s filing ...
Cached Biology Technology:Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 2Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 3Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 4Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit 2
(Date:10/15/2014)... 15, 2014 Sandata Technologies, LLC, an ... community-based care, today announced it released a case ... Electronic Visit Verification™ Solution (EVV™)  for Quality Care ... health company founded in 1996 and has five ... The study details the challenges facing ...
(Date:10/15/2014)... German Gauß-Allianz has admitted Johannes Gutenberg University Mainz ... Rhineland-Palatinate science hub continues to maintain a significant ... , "The acceptance of Johannes Gutenberg University ... is a milestone in the national and international ... The state of Rhineland-Palatinate can be proud that ...
(Date:10/15/2014)... Conn. , Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce market releases ... MarketSite in Times Square on Monday October 13 th . ... CTO David Tunnel and angel investor Mr. Chad ... Pereira , CEO of NXT-ID thanked his investors and employees "for ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... Access to Research Careers) Program has announced the travel ... of Chicanos and Native Americans in Science (SACNAS) annual ... These awards are meant to promote the entry of ... mainstream of the basic science community and to encourage ...
... Fox Foundation for Parkinson,s Research and Shake It Up ... Sydney,s Garvan Institute of Medical Research to look at ... Long non-coding RNAs are complex molecules, produced from ... in the body. Unlike conventional genes, they do not ...
... have increasingly relied on the wild and weedy relatives of ... and other traits. But just like all wild plant species, ... decline and extinction due to habitat loss, pollution, and climate ... describe the latest efforts to identify and protect the wild ...
Cached Biology News:Garvan Institute receives grant to research role of long non-coding RNAs in Parkinson's disease 2Protecting the weedy and wild kin of globally important crops 2